Army Medical Operational Capabilities for 2040 BAA

Executive Summary:

The MED CDID Broad Agency Announcement (BAA) invites industry and other performers to propose innovative medical concepts and technologies that support tactical Army medical units in the 2040 Future Operational Environment. The program is open through December 31, 2030, using a multi-step process: submission of a Vulcan Scout Card, followed—if selected for further interest—by a white paper and then a full technical and cost proposal. Companies should plan their internal timelines to first shape a high-impact Scout Card aligned to MED CDID’s three imperatives: clearing the battlefield, maximizing return to duty, and overcoming contested logistics.

How much funding would I receive?

The MED CDID BAA does not specify individual award ceilings or a total program funding limit. Instead, offerors must propose a Rough Order of Magnitude (ROM) total cost (including any fee) that is consistent with the scope of work, period of performance, and any dollar ranges specified in the announcement or follow-on calls. Common costs range from $500K to $5M.

What could I use the funding for?

Proposals should address at least one problem associated with the following aspects of the future operational environment (FOE):


a. Enemy action (through fires, maneuver, electronic warfare, etc.) will inhibit evacuation and medical resupply operations. Slow, reduced, or ineffective evacuation or medical resupply delays the Soldier’s treatment at the proper medical treatment facility. When evacuation slows, the consumption of medical treatment items increases, thus compounding the resupply problem. The cumulative effects of inadequate evacuation and medical resupply will reduce the return to duty rate and increase the number of preventable deaths.

b. The proliferation of drones, sensors, and other advanced technologies has made the modern battlefield more transparent than ever before. This transparency, coupled with long range precision and massed fires, requires Army forces to be distributed across a wider area and to displace frequently. Enemy precision and massed fires will result in more frequent mass casualty incidents, which will likely occur in support areas rather than near the front lines. Future medical forces must therefore be highly mobile to conduct survivability moves, to support widely distributed units, and to respond quickly to the point of need with both medical personnel and supplies (Class VIII).

c. The future battlefield will likely have a broad range of man-made and naturally occurring chemical and biological threats. These threats may be varied and difficult to detect and prevent, making early warning systems crucial. Toxic industrial chemicals and toxic industrial materials in urban areas pose additional threats. Directed energy and other new weapons may cause novel wound patterns that require new training and treatments.

d. When operating in urban areas, challenges include moving through routes blocked by rubble, craters, and other obstacles. Medical units must plan to extract patients from collapsed buildings, interaction with civil medical infrastructure, and potentially large numbers of injured civilians and enemy prisoners.

e. An increasingly transparent and lethal battlefield with chem-bio threats and new weapons systems will create continuous physiological and psychological stressors. These stressors will lead to a decline in the cognitive, physical, and emotional aspects of Soldier performance, and thus a decline in unit combat effectiveness. Army medical units must expand capacity to build and restore individual resiliency, to reduce disease non-battle injury (DNBI) losses, and increase return to duty (RTD).

AREAS OF INTEREST

The Army is looking for solutions in the following categories. Please note that these categories are not comprehensive, but rather to provide context. Categories may be created or removed as time progresses:

Are there any additional benefits I would receive?

Beyond the direct award, MED CDID funding offers significant strategic advantages for companies operating in defense, medical technology, logistics, AI/ML, and dual-use innovation:

Government Validation and Credibility:
Being selected by the U.S. Army Medical Capability Development Integration Directorate demonstrates strong technical merit and alignment with Army 2040 operational needs. This validation can accelerate engagement with primes, program offices, integrators, and investors who prioritize government-vetted technologies.

Enhanced Visibility and Notoriety:
Although the BAA does not explicitly promise publicity, MED CDID-aligned innovations often surface in Army medical modernization discussions, technical exchanges, and defense-sector forums—raising your company’s profile across DoD medical, logistics, and capability development communities.

Ecosystem Access and Collaboration Opportunities:
Awardees gain direct interaction with MED CDID, Army Futures Command stakeholders, and operational medical units. These touchpoints can open pathways to experimentation events, requirements discussions, field evaluations, and future contracting opportunities with Army, Joint, and SOF medical acquisition organizations.

Stronger Exit and Acquisition Potential:
Nondilutive DoD funding that advances medical, logistics, or autonomy technologies—combined with Army validation—typically increases a company’s valuation and attractiveness to acquirers in defense, biotech, medtech, autonomy, and advanced manufacturing. Government-backed maturity substantially strengthens both commercial and dual-use exit potential.

What is the timeline to apply and when would I receive funding?

Open period: The announcement is open from its posting date through December 31, 2030, as an open-ended BAA.

  • Submission cadence: Vulcan Scout Cards may be submitted at any time during the open period, subject to the process in the BAA. The government may also issue separate, focused calls for follow-on white papers at any time while the BAA is active.

  • Multi-step process:

    1. Vulcan Scout Card submission.

    2. If of interest, MED CDID may request a white paper and/or

    3. A formal technical and cost proposal.

The BAA does not specify review cycle timing or when funds would be awarded after a proposal is submitted. Actual award timing will depend on when MED CDID issues a request for proposal, internal evaluations, and contracting timelines.

Where does this funding come from?

This opportunity is issued by the U.S. Army Medical Capability Development Integration Directorate (MED CDID), which is responsible for enabling the Army Health System and developing future medical concepts and requirements for the Army and Joint Force

Who is eligible to apply?

The BAA does not restrict eligibility. Typical BAAs accept proposals from:

  • U.S. businesses of any size

  • Universities

  • Nonprofits

  • Federally-funded research and development centers (with limitations)

Foreign entities may be subject to additional restrictions depending on classification and export-control considerations.

What companies and projects are likely to win?

Based on the BAA’s emphasis, competitive projects are likely to:

  • Directly address one or more of the three MED CDID imperatives:

    • Clearing the battlefield (evacuation, prolonged care, integrated patient-movement C2).

    • Maximizing return to duty (resiliency, OPH, advanced diagnostics and treatment, training).

    • Overcoming contested logistics (advanced manufacturing, predictive MEDLOG, multimodal resupply).

  • Provide innovative, future-oriented solutions for the 2040 operational environment, not just incremental improvements to current practice.

  • Show clear relevance to the described FOE challenges (distributed forces, mass casualties, CBRN threats, urban operations, contested logistics).

  • Leverage cross-cutting enablers such as AI/ML, human-machine teaming, interoperability with joint and allied forces, and medical modeling and simulation to materially improve outcomes (reduced preventable deaths, higher RTD rates, more resilient logistics).

In short, teams that tightly map their concept to these problem statements and demonstrate operational impact for Corps-and-below medical units are best aligned with the BAA.

Are there any restrictions I should know about?

  • Tactical level focus: The BAA is focused on tactical-level (Army Corps and below) medical units, not broader health systems in isolation.

  • Targeted white papers: White papers should address only the specific portion of the BAA the offeror intends to accomplish. Submitting a single white paper that tries to cover the entire scope of the BAA is “most likely” to be rejected.

How long will it take me to prepare an application?

For a first-time applicant, preparing a competitive scout card under this BAA will likely take 20–30 hours in total.

How can BW&CO help?

Our team specializes in complex federal R&D proposals and can:

  • Triple your likelihood of success through proven strategy and insider-aligned proposal development

  • Reduce your time spent on the proposal by 50–80%, letting your team focus on technology and operations

  • Ensure you are targeting the best opportunity for your project and positioning your company for long-term growth under Federal & State R&D Initiatives.

How much would BW&CO Charge?

Our full service support is available to submit a scout card for a flat fee of $2,500.

Fractional support is $300 per hour, with most scout card projects requiring 10-12 hours of work.

For startups, we offer a discounted rate of $250 per hour to make top-tier grant consulting more accessible while maintaining the same level of strategic guidance and proposal quality.

Additional Resources

See solicitation on Vulcan

Previous
Previous

Drone Dominance Program (DDP) – One-Way Attack (OWA) sUAS Procurement

Next
Next

DLA Military Unique Sustainment Technology III (MUST-III) Broad Agency Announcement (BAA)